Abstract: A method for encouraging budding from a growing point of a plant, for inhibiting apical bud growth, and for increasing the number of lateral shoots is disclosed along with the substances made by and used in the method. The excrement produced by the larvae of rhinoceros beetles during growth is used to cause physiological phenomena of plants, such as encouraging a plant to bud (including laterally) or sucker, or inhibiting the growth of the apical bud of a woody plant. These special effects include those achievable by certain plant hormones.

Abstract: The present invention relates to a method of inhibiting Helicobacter pylori, principally using a compound A or a compound B for feedback inhibition of 3-dehydroquinate dehydratase in the shikimate pathway to inhibit Helicobacter pylori. The said compound A is one of the compounds as follows: benzoic acid, benzoic acid derivative, phenylacetic acid, phenylacetic acid derivative, trans-cinnaminic acid, 1,4-cyclohexanedicarboxylic acid, 4-indophenylboronic acid, phthalic acid and 3,4-dimethoxybenzyl alcohol. The said compound B is precursor of benzoic acid, benzoic acid derivative, phenylacetic acid or phenylacetic acid derivative generated by ?-oxidation of fatty acids.

Abstract: The present invention relates to a method for treating a Helicobacter pylori (IP) infection and/or an associated disease in an individual, comprising administering to the individual a therapeutically effective amount of a pharmaceutical composition containing a short-chain fatty acid or a pharmaceutically acceptable salt thereof, alone or in combination with an anti-HP agent, and a pharmaceutically acceptable carrier, wherein the short-chain fatty acid has the formula: in which R1 and R2, independently, are C1-C8alkyl or H, R3 is aryl or heteroaryl, and n is 0, 1, 2, 3, 4, 5 or 6. The present invention also relates to a method for treatment of Helicobacter pylori (HP) infection or disease associated with HP infection by administering a therapeutically effective amount of an HDAC inhibitor or a pharmaceutically acceptable salt thereof, alone or in combination with an anti-HP agent, and a pharmaceutically acceptable carrier.